Connect Biopharma is expected to report a Q2 2026 consensus loss of $0.32 per share on zero revenue, with the current $1.82 share price sitting significantly below the $6.25 average analyst price target.
Investors are primarily focused on the clinical development timeline for Rademikibart, particularly regarding Phase 3 data in Atopic Dermatitis and progress on regulatory filings in China. The market is also closely monitoring the company's cash runway and R&D spending following the Simcere partnership to ensure the company can fund operations through upcoming clinical readouts. Analysts expect these updates to dictate near-term volatility as the company moves toward potential commercialization.